Physician profile
Avinash Kaur
NPI 1598227308
$3,838.11
in general payments reported to CMS, 2019-2025
15 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $378 · 2024: $1,975 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,838.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,742.98 | 2023-2025 | |
| Lundbeck LLC | $546.83 | 2023-2025 | Vyepti |
| Pfizer INC. | $516.90 | 2023-2025 | |
| Lilly USA, LLC | $205.08 | 2023-2025 | Emgality, Zepbound, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $195.32 | 2024-2025 | Ajovy, Austedo Xr |
| Tonix Medicines, INC. | $178.88 | 2024-2025 | Zembrace Symtouch |
| Axsome Therapeutics, INC. | $141.50 | 2025 | Symbravo |
| Impel Pharmaceuticals LLC | $82.69 | 2025 | Trudhesa |
| Eisai INC. | $71.92 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $34.62 | 2024 | Onzetra Xsail |
| Medtronic, INC. | $32.19 | 2023 | Percept Pc Brainsense |
| Takeda Pharmaceuticals U.S.A., INC. | $27.93 | 2024 | Hyqvia |
| Cycle Pharmaceuticals INC | $24.20 | 2025 | Tascenso Odt |
| Genentech USA, INC. | $21.41 | 2024 | Ocrevus |
| Acadia Pharmaceuticals INC | $15.66 | 2024 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avinash Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.